<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004207</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067453</org_study_id>
    <secondary_id>LRI-103-UK-V1.1</secondary_id>
    <secondary_id>EU-99033</secondary_id>
    <nct_id>NCT00004207</nct_id>
  </id_info>
  <brief_title>Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study to Determine the Maximum Tolerated Dose of Daunoxome as Therapy for the Treatment of Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of liposomal daunorubicin in treating&#xD;
      patients who have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of daunorubicin liposomal in patients&#xD;
      with metastatic breast cancer. II. Assess the antineoplastic activity and safety profile of&#xD;
      this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients receive daunorubicin liposomal IV over a&#xD;
      minimum of 2 hours on day 1. Treatment repeats every 3 weeks for a maximum of 8 courses in&#xD;
      the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive&#xD;
      escalating doses of daunorubicin liposomal until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting&#xD;
      toxicity. Patients with stable or responding disease are followed at 1 and 3 months, then&#xD;
      every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15-20 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 1997</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal daunorubicin citrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically proven metastatic breast cancer&#xD;
        Measurable disease No bone metastases only No CNS involvement or leptomeningeal disease&#xD;
        Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance&#xD;
        status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil&#xD;
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL&#xD;
        Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) AST or ALT less than 2&#xD;
        times ULN (less than 5 times ULN if liver metastases present) Renal: Creatinine normal&#xD;
        Cardiovascular: Left ventricular ejection fraction at least 50% or normal by echocardiogram&#xD;
        or MUGA scan No active ischemic heart disease No uncontrolled hypertension No poorly&#xD;
        controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial infarction within&#xD;
        the past 6 months No symptomatic congestive heart failure, percutaneous transluminal&#xD;
        coronary angioplasty, or coronary artery bypass graft surgery within the past 12 months&#xD;
        Other: No other primary cancer within the past 5 years except curatively treated&#xD;
        nonmelanomatous skin cancer or carcinoma in situ of the cervix Not pregnant or nursing&#xD;
        Negative pregnancy test Fertile patients must use effective contraception No condition that&#xD;
        would preclude informed consent or compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior immunotherapy No&#xD;
        prior bone marrow transplantation Chemotherapy: Prior nonanthracycline based chemotherapy&#xD;
        for breast cancer allowed No prior anthracycline based chemotherapy for metastatic disease&#xD;
        Prior anthracycline based adjuvant chemotherapy allowed if: At least 6 months have elapsed&#xD;
        from completion of adjuvant therapy until the detection of metastatic disease Cumulative&#xD;
        dose no greater than 300 mg/m2 Endocrine therapy: At least 3 weeks since prior hormonal&#xD;
        therapy No concurrent hormonal or corticosteroid therapy for breast cancer Radiotherapy: At&#xD;
        least 2 weeks since prior radiotherapy and recovered No concurrent radiotherapy Surgery:&#xD;
        Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth O'Byrne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals, Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leicester Royal Infirmary NHS Trust</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2000</verification_date>
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>August 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2004</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

